RxDoctor Payments Data

Taiwo Fubara

Family · Dunn, NCNPI 1518554617

Payments from drug & device makers

$1,234in general payments, 2019–2025

Across 61 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$265
  • AbbVie$171
  • Amgen$151
  • Novartis$115
  • Boehringer Ingelheim$92
  • Exact Sciences$92
  • plus $349 from 10 others

What the payments were for

  • Food & beverage$1,234100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,234 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$58,445
Medicare patients
130
Services billed
1,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$73,796
EliquisApixaban63$71,113
TrulicityDulaglutide30$35,969
OzempicSemaglutide22$29,627
RybelsusSemaglutide15$21,912
MounjaroTirzepatide15$15,190
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$13,186
XareltoRivaroxaban11$12,479
Breo ElliptaFluticasone/Vilanterol23$9,124
FarxigaDapagliflozin Propanediol11$8,472
LinzessLinaclotide13$7,017
Repatha SureclickEvolocumab12$6,871
Tresiba Flextouch U-100Insulin Degludec12$5,918
VascepaIcosapent Ethyl11$5,240
SymbicortBudesonide/Formoterol Fumarate20$4,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$92$73,79667 claims
PfizerEliquis$87$71,11363 claims
Novo NordiskOzempic, Rybelsus$265$51,53937 claims
Lilly USA, LLCTrulicity, Mounjaro$68$51,15845 claims
AbbVieLinzess, Synthroid$171$9,71658 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Dunn

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →